The study achieved its primary endpoint as well as all key secondary endpoints. In June, the companies announced their plan to combine in an all-share transaction, subject to the pre-agreed Phase 2b success criteria for BPL-003 (mebufotenin benzoate). Atai Life Sciences ATAI and Beckley Psytech Limited jointly announced topline results from the eight-week, quadruple-masked, dose-finding core stage of the Phase 2b trial of a single dose of BPL-003 (intranasal mebufotenin (5-MeO-DMT) benzoate) in patients wit ...